Rod Raynovich | TalkMarkets | Page 15
CEO of Raygent Associates
Contributor's Links: Raygent
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a ...more

All Contributions

Latest Posts
225 to 240 of 366 Posts
<<< 1 ... 13 14 15 16 17 ... 23 >>>
Biotechs Fade Again In Late Day Sell-Off
Biotech stocks got a jump-start this morning but peaked quickly then abruptly sold off at about 2p. The IBB ended down 1.33% to 268.79 off recent five-day highs of $274 and considerably off post-election highs of $293.
Biotechs Mixed Hurt By Alexion And Ophthotech
Alexion - Company Fired its CEO and CFO on Sales Practices. Board member David Brennan and former CEO of AstraZeneca will take the helm. The third quarter report has been delayed on accounting issues and will be filed by mid - January.
Biotechs Unhinged By Tough Pricing Talk
Biotech stocks rallied briefly early in the week but sold off abruptly over the past two days with a quote from Trump in a Time Person of the Year article as saying, “I’m going to bring down drug prices”.
Market Reversal In Biotech But Healthcare Stocks Are Still Muddled
After one of the worst down days in months yesterday biotech stocks broadly reversed today giving a short term “nibble” signal.
Alert: Alzheimer’s Drug Fails In Clinical Trial - Stocks Sink
Another clinical trial failure for an Alzheimer’s Disease in a late stage trial triggered a pre-market sell-off.
Rayno Biobeat #4: Sector Shift Underway But What’s Next For Biotech?
Money flows show investors moving to a wide variety of equities to new highs as biotech stalls. This also could indicate a major shift from bonds to stocks with interest rates rising.
Rayno Biobeat #3…Trump Biotech Rally Leads Market Up
Nasdaq up over 1% to 5248. The Trump biotech rally began at today’s opening up 20 points to $280 then held to close up 8.9% to $285.
Rayno Biobeat #2…Good Value In Large Cap Biopharmaceuticals
Merck has become a major biotech player with their Keytruda lung cancer drug, a strong Phase II,III pipeline and 6% Q3 sales growth. MRK stock leads the group up 11.36% YTD despite the October downdraft.
Biotech Meltdown: Financial Metrics Offer Few Clues For What Is Next
We are almost through the earnings season and despite good results most biotech stocks are tanking. Stocks taking the biggest hits in October were: Amgen down 14.74%, Regeneron down 14%, Vertex down 12.3%, Abbvie down 11.4% and Biogen down 10.35%.
Biotech Bear Market Looking For Relief From Q3 Large Cap Growth
Momentum remains weak with successive days of the dreaded red screen. Although trading is active most stocks remain weak and are down YTD.
Biotechnology Bear Market: Trends To Watch For A 2016 Q4 Rally
IBB is at $270 midway between Brexit bottom of $242 and recent top of $300
Illumina Misses Revenue Forecast Causing Collateral Damage To Biotechs
Illumina shares crashed 25% to $139, after a warning on third quarter sales. The global leader in DNA sequencing systems warned that revenues missed forecast and would be $607M, well short of earlier guidance of $625-$630M.
Biotech Stocks Recovering From Last Week’s Free Fall
The IBB closed up 0.88% today to $290.8 about 10 points lower than the intermediate resistance and 6 points above 9/29 lows hit the day of the 3% drop. The XBI is a bit more volatile but clearly outperforms the IBB over one month with support at $60.
Rayno 2016 Life Science Portfolio Update
Biotech stocks are near their intermediate highs but still down in 2016 : IBB at $295 down 12.78% and the XBI​ at $67.80 down 3.42% YTD.
Biotech Stocks Pause At Resistance: IBB
Stocks were weak across the screen today withe the Nasdaq down 0.91% as investors may be distracted by the upcoming Presidential debates and the plethora of opinions on election politics affecting the market.
Biotech ETFs Lead Q3 Rally: XBI Breaks Out
The biotech sector is doing much better since BREXIT in late June despite a sell-off in late August. We are still trying to escape a bear market mentality because of the Q1 correction and concerns about drug prices.
225 to 240 of 366 Posts
<<< 1 ... 13 14 15 16 17 ... 23 >>>